期刊文献+
共找到162,606篇文章
< 1 2 250 >
每页显示 20 50 100
Redox,immune and genetic biomarker system for personalized treatments in colorectal cancer
1
作者 Anna Maria Berghella Anna Aureli +3 位作者 Angelica Canossi Tiziana Del Beato Alessia Colanardi Patrizia Pellegrini 《世界胃肠肿瘤学杂志:英文版(电子版)》 CAS 2019年第2期117-138,共22页
BACKGROUND Identifying biomarkers for the risk of developing degenerative processes linked to aging and colorectal cancer(CRC)onset that could improve clinical strategies.AIM To determine valid targets and a predictiv... BACKGROUND Identifying biomarkers for the risk of developing degenerative processes linked to aging and colorectal cancer(CRC)onset that could improve clinical strategies.AIM To determine valid targets and a predictive biomarker’s system of chronicization of inflammation for cancer treatment.METHODS A group of 147 CRC patients was studied.Clinical diagnosis was confirmed histopathologically,and patients were sub-typed using the pathological tumornode-metastasis classification.Thirteen colon adenoma patients and 219 healthy subjects were also studied.A system biology study on Thioredoxin1/CD30 redox-immune systems(Trx1/CD30),T helper cytokines and polymorphisms of killer immunoglobulin-like receptors,FcγRIIa-131H/R and FcγRIIIa-158V/F was carried out.Enzyme-linked immunosorbent assay was performed to analyze sera.Genetic study was executed by polymerase chain reaction sequence-specific primers and sequence-based typing method.Statistical analysis was performed by using the“Statgraphics software systems”.RESULTS We found a positive increase between Trx1/RTrx1 levels and sCD30 level and increased age.With respect to the gender relationships,there were distinct differences.Females showed a primary relationship between transforming growth factor beta(TGFβ)with Trx1,whereas males had one with TGFβand RTrx1.Trx1/CD30 controls the redox immune homeostasis,and an imbalance in the relationship between the Trx1/RTrx1 and sCD30 levels is linked to the onset and progression of tumor.This event happens through different gender-specific cytokine pathways.Our study demonstrated that the serum levels of Trx1/RTrx1,TGFβ/interleukin(IL)6 and TGFβ/IL4 combinations and the sCD30,IFNγand IL2 combination constitute a predictive gender specific biomarker system.This is relevant for clinical screening to detect the risk of the potential development or progression of a tumor.CONCLUSION Oxidative stress on Trx1/CD30 is a trigger of cancer disease,and the selected oxidation and immune products are a biomarker system for aging a 展开更多
关键词 AGING and CANCER BIOMARKER CANCER personalized treatments Oxidation and IMMUNE biomarkers Trx1/CD30 target KIRs and FCΓR polymorphisms Th cytokines AGING and disease Cancer-related mechanisms
在线阅读 免费下载
碳离子治疗恶性肿瘤研究进展
2
作者 陈威佐 唐君霞 +2 位作者 赵达 关泉林 潘婷婷 《中国肿瘤》 CAS CSCD 北大核心 2019年第3期208-213,共6页
碳离子束放射治疗因其精确的剂量分布、理想的生物效应及动态束流监控等优点,在强力杀伤肿瘤的同时可明显降低对正常组织的损伤及缩减治疗时间,对腺样囊性癌、骨肉瘤、软骨肉瘤、肝细胞肝癌等的治疗疗效被广泛认可,该项技术在德国、日... 碳离子束放射治疗因其精确的剂量分布、理想的生物效应及动态束流监控等优点,在强力杀伤肿瘤的同时可明显降低对正常组织的损伤及缩减治疗时间,对腺样囊性癌、骨肉瘤、软骨肉瘤、肝细胞肝癌等的治疗疗效被广泛认可,该项技术在德国、日本等国家发展较迅速,我国目前正处于临床试验阶段。文章就碳离子治疗肿瘤的原理、优势及临床研究现状进行综述。 展开更多
关键词 碳离子束 恶性肿瘤 肺癌 肝癌 放射治疗
DNA甲基转移酶3B-149C>T多态性与致癌风险相关性的Meta分析 预览
3
作者 吴雯 李萍 +5 位作者 左然 曾庆波 吴德生 谢妮 龙鼎新 袁建辉 《癌变.畸变.突变》 CAS 2019年第2期102-110,共9页
目的:评估DNA甲基转移酶3B-149C>T(DNMT3B-149C>T)多态性与致癌风险之间的相关性。方法:依据Newcastle-Ottawa Scale(NOS)文献质量评价量表,对1990~2017年国内外公开发表的相关文献进行评价并提取资料;对DNMT3B-149C>T各基因... 目的:评估DNA甲基转移酶3B-149C>T(DNMT3B-149C>T)多态性与致癌风险之间的相关性。方法:依据Newcastle-Ottawa Scale(NOS)文献质量评价量表,对1990~2017年国内外公开发表的相关文献进行评价并提取资料;对DNMT3B-149C>T各基因型模型进行比较,包括CC与TT、CT与TT、CC+CT与TT,综合分析其在病例组和对照组中的分布情况;通过Q检验和I^2值分析各研究间的异质性,应用Begg秩相关法和Egger回归法验证发表偏倚,使用Review Manager 5.0软件和STATA version 12.0进行统计分析,计算比值比(OR)及95%置信区间(95%CI),评估DNMT3B-149C>T多态性与致癌风险的相关性。结果:分析文献中的7612名癌症病例和9679名健康对照。按不同癌症类型进行亚组分析,DNMT3B-149C>T多态性与肺癌的患病存在相关性[OR=1.51,95%CI(1.08,2.12),P=0.02]。结论:DNMT3B-149C>T多态性可能是肺癌的易感性因素。 展开更多
关键词 DNA甲基转移酶3B 单核苷酸多态性 癌症 META分析 肺癌
在线阅读 下载PDF
2015年上海市恶性肿瘤流行特征分析 预览
4
作者 鲍萍萍 吴春晓 +9 位作者 张敏璐 彭鹏 王春芳 龚杨明 顾凯 向詠梅 施亮 庞怡 施燕 付晨 《中国癌症杂志》 CAS CSCD 北大核心 2019年第2期81-99,共19页
背景与目的:恶性肿瘤严重威胁着居民健康,已成为重大的公共卫生问题。本研究旨在描述和分析2015年上海市恶性肿瘤流行特征。方法:根据上海市恶性肿瘤病例报告登记系统收集的恶性肿瘤发病和死亡资料,按地区、性别分层,分别计算恶性肿瘤... 背景与目的:恶性肿瘤严重威胁着居民健康,已成为重大的公共卫生问题。本研究旨在描述和分析2015年上海市恶性肿瘤流行特征。方法:根据上海市恶性肿瘤病例报告登记系统收集的恶性肿瘤发病和死亡资料,按地区、性别分层,分别计算恶性肿瘤发病与死亡粗率、标化率、前10位恶性肿瘤发病与死亡顺位和构成等,并应用Joinpoint统计软件分析2002—2015年上海市肺癌发病和死亡趋势,估算总体和分阶段的年度变化百分比(annual percent change,APC)。采用Segi’s世界标准人口年龄构成计算标化率。结果:2015年上海市共报告恶性肿瘤新发病例71 610例,死亡病例38 445例。病理学诊断比例(percentage of morphologically verified cases,MV%)为78.42%,只有死亡医学证明书比例(percentage of death certifications only,DCO%)为0.21%,死亡发病比(mortality to incidence ratio,M/I)为0.55。上海市恶性肿瘤粗发病率为497.33/10万,标化发病率为228.82/10万,男性标化发病率低于女性,市区低于郊区。恶性肿瘤发病在40岁以后快速上升,在80~84岁年龄组达到高峰。全市发病前10位恶性肿瘤依次为肺癌、结直肠癌、甲状腺癌、胃癌、乳腺癌、肝癌、前列腺癌、胰腺癌、脑和中枢神经系统肿瘤以及膀胱癌,前10位恶性肿瘤占全部恶性肿瘤发病的76.59%。全市恶性肿瘤粗死亡率为267.00/10万,标化死亡率为95.99/10万,男性标化死亡率高于女性,市区和郊区基本持平。死亡率在45岁以后快速上升,在≥85岁年龄组达到高峰。死亡前10位恶性肿瘤依次为肺癌、结直肠癌、胃癌、肝癌、胰腺癌、乳腺癌、食管癌、胆囊癌、前列腺癌以及脑和中枢神经系统肿瘤,前10位恶性肿瘤占全部恶性肿瘤死亡的78.07%。截至2016年12月31日,上海市共有399 027例现患肿瘤病例,现患率为2.77%。市区现患率为3.07%,郊区为2.55%。乳腺癌是现患病例中最常见的恶性肿瘤,占15.33%。� 展开更多
关键词 恶性肿瘤 发病率 死亡率 趋势 肺癌
在线阅读 下载PDF
Hong Kong female’s breast cancer awareness measure: Crosssectional survey
5
作者 May Pui Shan Yeung Emily Ying Yang Chan +2 位作者 Samuel Yeung Shan Wong Benjamin Hon Kei Yip Polly Suk-Yee Cheung 《世界临床肿瘤学杂志(英文版)》 2019年第2期98-109,共12页
BACKGROUND In women worldwide, breast cancer is the most common cancer. Breast cancer accounted for 26.6% of all new cancers in females diagnosed in 2015 in Hong Kong. AIM To examine women’s awareness, perception, kn... BACKGROUND In women worldwide, breast cancer is the most common cancer. Breast cancer accounted for 26.6% of all new cancers in females diagnosed in 2015 in Hong Kong. AIM To examine women’s awareness, perception, knowledge, and screening practice of breast cancer in Hong Kong. METHODS We carried out a population-based survey using random telephone interviews to women aged 18 or above using the United Kingdom Cancer Research Breast Cancer Awareness Measure (United Kingdom CAM). The data was analysed using proportions, chi-square test (χ2-test) and adjusted odds ratios (ORs). RESULTS A total of 1000 participants completed the CAM questionnaire from 1,731 responses (response rate = 57.8%) from September to October 2017. One in five and one in four respondents recalled ≥ 3 early warning signs and ≥ 2 risk factors of breast cancer respectively. The majority (62.6%) reported they were not confident that they would notice a change in their breasts. Among the respondents, 16.8% would have regular mammography at least every two years.In general, 4 in 10 women had tried practices on preventing breast cancer. Respondents with better result in recalling breast cancer signs and symptoms were more likely to seek immediate medical help when noticed a change in their breasts (χ^2-test P = 0.038), and more likely had tried prevention practice (χ^2-test P < 0.001). Respondents received higher education (secondary school or above) had higher breast cancer awareness (OR = 2.83, CI: 1.61-4.97), more frequent screening (OR = 2.64, CI: 1.63-4.26) and more had tried prevention practices (OR = 2.80, CI: 1.96-4.02) when compared to those with lower education. Those in age groups 31- 45 and 46-60 had higher percentages in performing breast self-exam and mammography when compared to the 18-30 and 61 or above age groups. CONCLUSION Population-wide public health initiatives should emphasize on prevention and early detection of breast cancer in women, with targeted strategy for those with low education level and advance in age. 展开更多
关键词 BREAST CANCER CANCER AWARENESS MEASURE AWARENESS Screening practice Behaviour ATTITUDE
在线阅读 免费下载
益气养阴解毒方辅助厄洛替尼靶向治疗对晚期非小细胞肺癌患者血清糖类抗原199、环氧化酶2和免疫功能的影响
6
作者 吴春晓 缪佳 《河北中医》 2019年第2期238-242,共5页
目的 观察益气养阴解毒方辅助厄洛替尼靶向治疗对晚期非小细胞肺癌(NSCLC)患者血清糖类抗原199(CA199)、环氧化酶-2(COX-2)和免疫功能的影响。方法 将86例晚期NSCLC患者按照随机数字表法分为2组。对照组43例采用厄洛替尼靶向治疗;治疗... 目的 观察益气养阴解毒方辅助厄洛替尼靶向治疗对晚期非小细胞肺癌(NSCLC)患者血清糖类抗原199(CA199)、环氧化酶-2(COX-2)和免疫功能的影响。方法 将86例晚期NSCLC患者按照随机数字表法分为2组。对照组43例采用厄洛替尼靶向治疗;治疗组43例在对照组治疗基础上加用益气养阴解毒方治疗。2组均持续治疗2个月。观察2组治疗前后中医证候改善情况及血清CA199、COX-2水平,外周血CD3^+、CD4^+、CD8^+、自然杀伤(NK)细胞比例和CD4^+/CD8^+值,比较2组临床疗效。结果 治疗组病情控制率(83.72%)高于对照组(62.79%, P <0.05),临床疗效优于对照组。治疗组中医证候改善总有效率(88.37%)高于对照组(69.77%, P <0.05)。治疗后2组血清CA199、COX-2水平均较本组治疗前明显降低( P <0.05),且治疗组低于对照组( P <0.05)。治疗后治疗组CD3^+、CD4^+、NK细胞比例及CD4^+/CD8^+均较本组治疗前升高( P <0.05),CD8^+比例明显降低( P <0.05),且与对照组治疗后比较差异均有统计学意义( P <0.05)。结论 益气养阴解毒方配合厄洛替尼靶向治疗有助于提高晚期NSCLC患者治疗效果,降低血清CA199、COX-2水平,改善免疫功能。 展开更多
关键词 非小细胞肺癌 益气养阴 中药疗法 抗原 肿瘤相关 碳水化合物 糖类抗原199 环氧化酶2 免疫功能
在线阅读 免费下载
肿瘤疫苗临床研究评价及进展
7
作者 黄芸 高建鹏 王辉 《肿瘤学杂志》 CAS 2019年第3期196-201,共6页
肿瘤疫苗是近年来肿瘤疾病的新兴治疗手段之一,其种类繁多,疗效显著,有着良好的应用前景。肿瘤疫苗可分为全细胞疫苗、多肽疫苗、基因工程疫苗和单克隆抗体疫苗等类别。2011~2017年间有15个肿瘤疫苗类新药获批上市,实现了基础研发到临... 肿瘤疫苗是近年来肿瘤疾病的新兴治疗手段之一,其种类繁多,疗效显著,有着良好的应用前景。肿瘤疫苗可分为全细胞疫苗、多肽疫苗、基因工程疫苗和单克隆抗体疫苗等类别。2011~2017年间有15个肿瘤疫苗类新药获批上市,实现了基础研发到临床应用的迈进,为肿瘤的治疗模式带来了令人振奋的变革。全文就近几年肿瘤疫苗领域的新药从分类、作用机制及临床应用进展方面作一综述。 展开更多
关键词 肿瘤 肿瘤疫苗 免疫治疗
Stereotactic body radiation therapy for non-small cell lung cancer:A review
8
作者 Kavitha M Prezzano Sung Jun Ma +3 位作者 Gregory M Hermann Charlotte I Rivers Jorge A Gomez-Suescun Anurag K Singh 《世界临床肿瘤学杂志(英文版)》 2019年第1期14-27,共14页
Stereotactic body radiation therapy(SBRT)is the treatment of choice for medically inoperable patients with early stage non-small cell lung cancer(NSCLC).A literature search primarily based on PubMed electronic databas... Stereotactic body radiation therapy(SBRT)is the treatment of choice for medically inoperable patients with early stage non-small cell lung cancer(NSCLC).A literature search primarily based on PubMed electronic databases was completed in July 2018.Inclusion and exclusion criteria were determined prior to the search,and only prospective clinical trials were included.Nineteen trials from 2005 to 2018 met the inclusion criteria,reporting the outcomes of 1434 patients with central and peripheral early stage NSCLC.Patient eligibility,prescription dose and delivery,and follow up duration varied widely.Threeyears overall survival ranged from 43%to 95%with loco-regional control of up to 98%at 3 years.Up to 33%of patients failed distantly after SBRT at 3 years.SBRT was generally well tolerated with 10%-30%grade 3-4 toxicities and a few treatment-related deaths.No differences in outcomes were observed between conventionally fractionated radiation therapy and SBRT,central and peripheral lung tumors,or inoperable and operable patients.SBRT remains a reasonable treatment option for medically inoperable and select operable patients with early stage NSCLC.SBRT has shown excellent local and regional control with toxicity rates equivalent to surgery.Decreasing fractionation schedules have been consistently shown to be both safe and effective.Distant failure is common,and chemotherapy may be considered for select patients.However,the survival benefit of additional interventions,such as chemotherapy,for early stage NSCLC treated with SBRT remains unclear. 展开更多
关键词 LUNG CANCER NON-SMALL cell LUNG CANCER STEREOTACTIC body radiation therapy STEREOTACTIC ABLATIVE radiotherapy DISTANT failure
在线阅读 免费下载
Preoperative Short-Course Radiation Therapy in Rectal Cancer 预览
9
作者 Pham Nguyen Tuong Pham Nguyen Cuong +2 位作者 Le Trong Hung Nguyen Thanh Ai Huynh Thanh Hai 《美中医学:英文版》 2019年第2期100-104,共5页
Purpose:To evaluate the benefits of preoperative short-course radiotherapy in locally advanced rectal cancer.Patients and methods:A prospective study of 30 rectal cancer patients at T3-4M0 stage and ECOG 0-2 performed... Purpose:To evaluate the benefits of preoperative short-course radiotherapy in locally advanced rectal cancer.Patients and methods:A prospective study of 30 rectal cancer patients at T3-4M0 stage and ECOG 0-2 performed preoperative short-course radiation therapy at Hue Central Hospital Vietnam between June 2016 and July 2018,using pelvic 3D-Conformal Radiation Therapy with the total radiation dose being 25 Gy in 5 fractions over five days.Results:Mean age 57.1±13.6 with 46.7%of patients in the range of 41-60 year-old.Male/female ratio:2/1.Tumour stage T3 and T4 was 70%and 30%,respectively;stage III and stage IV was 86.7%and 13.3%,respectively.Positive lymph node rates on endoscopic ultrasound were 85.7%in T3 and 77.8%in T4.Downstaging rate for stage III,T4 and T3 was 65.4%,65.4%and 4.8%,respectively.For upper third of the rectum:100%of T3 stage patients got no downstaging.For middle rectum:downstaging rate for stage III,T4 and T3 was 55.6%,57.1%and 7.1%,respectively.For lower rectum:downstaging rate for stage III,T4 was 50.0%and 100.0%,respectively.No acute toxicity was seen,86.7%of the patients performed laparoscopic sphincter-preserving surgery.Conclusion:For the treatment of locally advanced rectal cancer,neoadjuvant therapy is standard.Preoperative short-course radiation therapy is a reasonable therapeutic option because it demonstrates benefits in tumour downstaging especially for middle and lower rectum. 展开更多
关键词 Rectal cancer short-course RADIATION THERAPY PREOPERATIVE DOWNSTAGING PELVIC 3D-conformal RADIATION therapy.
在线阅读 下载PDF
Comparison of efficacy and safety between late-course and simultaneous integrated dose-increasing intensity-modulated radiation therapy for cervical cancer complicated with pelvic lymph node metastasis 预览
10
作者 Yi Cheng Nan Huang +3 位作者 Jing Zhao Jianhua Wang Chen Gong Kai Qin 《肿瘤学与转化医学:英文版》 2019年第1期25-29,共5页
Objective This study aimed to compare and analyze the clinical efficacy and safety of late-course and simultaneous integrated dose-increasing intensity-modulated radiation therapy(IMRT) for cervical cancer complicated... Objective This study aimed to compare and analyze the clinical efficacy and safety of late-course and simultaneous integrated dose-increasing intensity-modulated radiation therapy(IMRT) for cervical cancer complicated with pelvic lymph node metastasis. Methods Sixty patients with cervical cancer complicated with pelvic lymph node metastasis who were admitted to our hospital from January 2013 to January 2015 were enrolled. The patients were randomly divided into the late-course dose-increasing IMRT group and the simultaneous integrated dose-increasing IMRT group, with 30 cases included in each group, respectively. All patients were concurrently treated with cisplatin. After treatment, the clinical outcomes of the two groups were compared. Results The remission rate of symptoms in the simultaneous integrated dose-increasing IMRT group was significantly higher than that in the late-course dose-increasing IMRT group(P < 0.05). The follow-up results showed that the overall survival time, progression-free survival time, and distant metastasis time of patients in the simultaneous integrated dose-increasing IMRT group were significantly longer than those in the late-course dose-increasing IMRT group(P < 0.05). The recurrent rate of lymph nodes in the radiation field in the simultaneous integrated dose-increasing IMRT group was significantly lower(P < 0.05) than in the late-course dose-increasing IMRT group. There was no significant difference in the incidence of cervical and vaginal recurrence and distant metastasis between the two groups(P > 0.05). The radiation doses of Dmax in the small intestine, D1 cc(the minimum dose to the 1 cc receiving the highest dose) in the bladder, and Dmax in the rectum in the simultaneous integrated dose-increasing IMRT group were significantly lower(P < 0.05) than in the late-course dose-increasing IMRT group. There was no significant difference in intestinal D2 cc(the minimum dose to the 2 cc receiving the highest dose) between the two groups(P > 0.05). The incidence of bone marrow suppr 展开更多
关键词 simultaneous integrated dose-increasing INTENSITY-MODULATED radiation therapy late-course dose-increasing INTENSITY-MODULATED radiation therapy cervical cancer COMPLICATED with pelvic lymph node metastasis clinical efficacy safety
在线阅读 下载PDF
李佩文运用药对治疗癌症经验探析
11
作者 龙麟 陈静 +2 位作者 张叶熙 李佩文 付文胜 《中华中医药杂志》 CAS CSCD 北大核心 2019年第1期137-140,共4页
文章总结分析李佩文教授中医药治疗癌症常用的药对规律及学术经验,为临床诊疗癌症提供借鉴,明确李老临证中常用药对作用机制及疗效,李老临床中用药精简,药对精当,疗效明显,方中药对运用具有临床研究价值。
关键词 癌症 药对 用药规律 学术经验 李佩文
Role of pancreatoscopy in management of pancreatic disease:A systematic review
12
作者 Tarun Kaura Field F Willingham Saurabh Chawla 《世界胃肠内镜杂志:英文版(电子版)》 2019年第2期155-167,共13页
BACKGROUND Per-oral pancreatoscopy(POP)plays a role in the diagnosis and therapy of pancreatic diseases.With recent technological advances,there has been renewed interest in this modality.AIM To evaluate the efficacy ... BACKGROUND Per-oral pancreatoscopy(POP)plays a role in the diagnosis and therapy of pancreatic diseases.With recent technological advances,there has been renewed interest in this modality.AIM To evaluate the efficacy and safety of POP in management of pancreatic stone disease and pancreatic ductal neoplasia.METHODS To determine the safety and efficacy of POP in the management of pancreatic diseases,a systematic search was conducted in MEDLINE,EMBASE and Ovid.Articles in languages other than English and case reports were excluded.All published case series were eligible.Data specific to POP were extracted from studies,which combined cholangiopancreatoscopy.Ten studies were included in the analysis of POP therapy for pancreatic stone disease,and 15 case series satisfied the criteria for inclusion for the role of POP in the management of pancreatic ductal neoplasia.The examined data were subcategorized according to adjunctive modalities,such as direct tissue sampling,cytology,the role of intraoperative POP,intraductal ultrasound(IDUS)and POP combined with image-enhancing technology.RESULTS The success rate for complete ductal stone clearance ranged from 37.5%-100%.Factors associated with failure included the presence of strictures,multiple stones and the inability to visualize the target area.Although direct visualization can identify malignant and premalignant conditions,there is significant overlap with benign diseases.Visually-directed biopsies provide a high degree of accuracy,and represent a unique approach for tissue acquisition in patients with ductal abnormalities.Addition of pancreatic fluid cytology increases diagnostic yield for indeterminate lesions.Protrusions larger than 3 mm noted on IDUS are significantly more likely to be associated with malignancy.The rate of adverse events associated with POP ranged from 0%-35%.CONCLUSION Current evidence supports wider adoption of pancreatoscopy,as it is safe and effective.Improved patient selection and utilization of novel technologies may further enhance its rol 展开更多
关键词 PANCREATOSCOPY Cholangiopancreatoscopy Chronic pancreatitis PANCREATIC DUCT stones INTRADUCTAL papillary MUCINOUS neoplasm PANCREATIC cancer PANCREATIC DUCT STRICTURE
在线阅读 免费下载
Progress in the diagnosis and treatment of extensive-stage small cell lung cancer 预览
13
作者 Fei Xu Xiaoli Ren +4 位作者 Yuan Chen Qianxia Li Ruichao Li Yu Chen Shu Xia 《肿瘤学与转化医学:英文版》 2019年第1期33-42,共10页
Lung cancer, being the most common cancer type, accounts for 13% of all newly diagnosed malignant tumors globally each year. Small cell lung cancer (SCLC) accounts for approximately 15% of newly diagnosed lung cancers... Lung cancer, being the most common cancer type, accounts for 13% of all newly diagnosed malignant tumors globally each year. Small cell lung cancer (SCLC) accounts for approximately 15% of newly diagnosed lung cancers each year, but its annual death toll accounts for 25% of that of lung cancer. We summarized relevant clinical studies to elaborate the epidemiology, pathological and clinical characteristics and the treatment status of small cell lung cancer. This paper first described the epidemiology and the pathological and clinical characteristics of SCLC and the systematic treatment of extensive-stage SCLC and then introduced the current targeted therapy and immunotherapy for SCLC to provide clinicians and patients with a more systematic, comprehensive, and beneficial treatment regimen. We expect that these studies can provide clinicians with a clear direction in molecularly targeted therapy or immunotherapy, so that a treatment approach with better antitumor effects and longer-lasting clinical benefits can be provided to the patients. 展开更多
关键词 small cell LUNG cancer (SCLC) extensive-stage TARGETED therapy IMMUNOTHERAPY
在线阅读 下载PDF
787例抗肿瘤药物不良反应特点及预后因素分析
14
作者 王娜娜 白羽 +2 位作者 刘红 李雪梅 张艳华 《肿瘤药学》 CAS 2019年第1期143-148,共6页
目的 探讨抗肿瘤药物不良反应(Adverse drug reaction,ADR)的特点、规律和转归情况,为临床安全用药提供参考依据。方法 回顾性分析北京大学肿瘤医院2015年1月-2017年12月期间上报的抗肿瘤药物相关ADR报告。分析患者原发疾病分布,不同药... 目的 探讨抗肿瘤药物不良反应(Adverse drug reaction,ADR)的特点、规律和转归情况,为临床安全用药提供参考依据。方法 回顾性分析北京大学肿瘤医院2015年1月-2017年12月期间上报的抗肿瘤药物相关ADR报告。分析患者原发疾病分布,不同药物发生ADR情况,并探究与ADR预后相关的临床因素。结果 787例ADR报告中,患者平均年龄(54.80±12.42)岁,其中男性365例,女性422例,严重ADR 34例。患者发生的ADR经停药或治疗后,痊愈257例,好转484例,未好转11例。原患疾病以肺癌、乳腺癌居多,分别为175例和151例。常见ADR为骨髓抑制和过敏反应/过敏性休克。环磷酰胺患者易发生严重ADR,而多西他赛导致的ADR痊愈率较高,顺铂的ADR痊愈率较低。此外,体重≤60 kg的患者ADR痊愈率较高,胃癌患者ADR预后较好,而肺癌患者ADR预后较差。多因素分析显示,在肺癌、乳腺癌和胃癌患者中,抗肿瘤药物种类、患者ADR数目是ADR的独立预后预测因子。结论 不同肿瘤患者临床特征、肿瘤药物的ADR特点和预后不同,临床上应预估ADR风险以供制定治疗方案时参考,并加强治疗后ADR的预防和管理。 展开更多
关键词 肿瘤治疗 药物不良反应 预后
在线阅读 免费下载
Association between Pri-miR-34b/c rs4938723 polymorphism and bladder cancer risk
15
作者 Mohammad Hashemi Vahed Hasanpour +2 位作者 Hiva Danesh Fatemeh Bizhani Behzad Narouie 《生物医学研究杂志:英文版》 CAS CSCD 2019年第1期24-29,共6页
Several studies examined the impact ofmiR-34b/c rs4938723 polymorphism and cancer ri此,but the findings are inconsistent.However,no study has been conducted to inspect the impact of miR-34b/c polymorphism on bladder c... Several studies examined the impact ofmiR-34b/c rs4938723 polymorphism and cancer ri此,but the findings are inconsistent.However,no study has been conducted to inspect the impact of miR-34b/c polymorphism on bladder cancer.This study aimed to assess possible association between rs4938723 polymorphism and bladder cancer risk.This case-con位01 study was done on 136 pathologically proven bladder cancerpatients and 144 controls.Genotyping of Pri-miR-34b/c rs4938723 polymo叩hism was achieved by using the polymerase chain reaction restriction企agment length polymorphismσCR-RFLP)method.Our findings did not show any statistically significant differences in genotype and allele企equencies between bladder cancer and controls.Larger sample sizes with diverse ethnicities are required to validate our findings. 展开更多
关键词 Pri-miR-34b/c BLADDER cancer POLYMORPHISM microRNA
在线阅读 免费下载
Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer
16
作者 Yasuhito Suenaga Mitsuro Kanda +12 位作者 Seiji Ito Yoshinari Mochizuki Hitoshi Teramoto Kiyoshi Ishigure Toshifumi Murai Takahiro Asada Akiharu Ishiyama Hidenobu Matsushita Chie Tanaka Daisuke Kobayashi Michitaka Fujiwara Kenta Murotani Yasuhiro Kodera 《世界胃肠肿瘤学杂志:英文版(电子版)》 CAS 2019年第1期17-27,共11页
AIM To evaluate the prognostic significance of perioperative carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels in stage II/III gastric cancer.METHODS From a multi-institutional retrospective... AIM To evaluate the prognostic significance of perioperative carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels in stage II/III gastric cancer.METHODS From a multi-institutional retrospective database compiled by integrating clinical data from nine institutions, data of 998 patients who underwent curative resection for stage II/III gastric cancer between 2010 and 2014 were retrieved and analyzed. The prognostic impact of the preoperative and postoperative levels and chronological changes in CEA, CA19-9 and their combination were evaluated. To test whether postoperative adjuvant chemotherapy alters the prognostic impact of perioperative CEA and CA19-9 levels, the hazard ratios for mortality were compared between patients who underwent surgery alone and patients who underwent surgery followed by adjuvant chemotherapy. RESULTS The prognostic impact of postoperative CEA and CA19-9 was superior to that of the preoperative levels. Multivariable analysis identified high postoperative CEA and CA19-9 levels as independent prognostic factors for overall survival. Disease-free survival rates clearly decreased in a stepwise manner in association with postoperative CEA and CA19-9 levels, and patients with high levels of both markers showed significantly poorer prognosis than other patient groups. When we analyzed perioperative changes in serum CEA and CA19-9 levels, patients with high levels before and after surgery had the worst disease-free survival rates among all patient groups. Patients with normalized CEA levels after surgery had a significantly lower disease-free survival rate than those with normal perioperative levels, whereas patients with normalized CA19-9 levels after surgery had equivalent survival to those with normal perioperative levels. The prognostic impact of high CEA levels was observably smaller in patients who underwent adjuvant chemotherapy than in patients who underwent surgery alone, whereas that of high CA19-9 was greater in patients who underwent adjuvant chemotherapy. High 展开更多
关键词 Gastric cancer Carcinoembryonic ANTIGEN CARBOHYDRATE ANTIGEN 19-9 PERIOPERATIVE LEVELS Prognosis
在线阅读 免费下载
Impact of time from diagnosis to chemotherapy in advanced gastric cancer: A Propensity Score Matching Study to Balance Prognostic Factors
17
作者 Tsutomu Nishida Aya Sugimoto +11 位作者 Ryo Tomita Yu Higaki Naoto Osugi Kei Takahashi Kaori Mukai Tokuhiro Matsubara Dai Nakamatsu Shiro Hayashi Masashi Yamamoto Sachiko Nakajima Koji Fukui Masami Inada 《世界胃肠肿瘤学杂志:英文版(电子版)》 CAS 2019年第1期28-38,共11页
BACKGROUND It is unclear whether treatment delay affects the clinical outcomes of chemotherapy in advanced gastric cancer (A-GC). AIM To assess whether treatment delay affects the clinical outcomes of chemotherapy in ... BACKGROUND It is unclear whether treatment delay affects the clinical outcomes of chemotherapy in advanced gastric cancer (A-GC). AIM To assess whether treatment delay affects the clinical outcomes of chemotherapy in A-GC. METHODS This single-center retrospective study examined consecutive patients with A-GC between April 2012 and July 2018. In total, 110 patients with stage IV A-GC who underwent chemotherapy were enrolled. We defined the wait time (WT) as the interval between diagnosis and chemotherapy initiation. We evaluated the influence of WT on overall survival (OS). RESULTS The mean OS was 303 d. The median WT was 17 d. We divided the patients into early and elective WT groups, with a 2-wk cutoff point. There were 46 and 64 patients in the early and elective WT groups, respectively. Compared with the elective WT group, the early WT group had significantly lower albumin (Alb) levels and higher neutrophil/lymphocyte ratios and C-reactive protein (CRP) levels but not a lower performance status. The elective WT group underwent more combination chemotherapy than did the early WT group. OS was different between the two groups (230 d vs 340 d, respectively). Multivariate analysis revealed that higher CRP levels, lower Alb levels and monotherapy were significantly related to a poor prognosis. To minimize potential selection bias, patients in the elective WT group were 1:1 propensity score matched with patients in the early WT group; no significant difference in OS was found (303 d vs 311 d, respectively, log-rank P = 0.9832). CONCLUSION A longer WT in patients with A-GC does not appear to be associated with a worse prognosis. 展开更多
关键词 Advanced gastric cancer WAITING TIME CHEMOTHERAPY PROGNOSIS Overall survival
在线阅读 免费下载
癌症患者病耻感的的测评工具及现状水平的研究进展
18
作者 王欣 高婕 《护士进修杂志》 2019年第4期314-318,共5页
癌症是世界严重的公共卫生问题,根据国际癌症研究机构的数据[1]显示,全球每年约800万人死于癌症。目前我国癌症的发病率为0.286%,平均每分钟就有6人被诊断为恶性肿瘤[1]。癌症是严重影响居民健康的危险因素,给患者家庭和社会带来沉重负... 癌症是世界严重的公共卫生问题,根据国际癌症研究机构的数据[1]显示,全球每年约800万人死于癌症。目前我国癌症的发病率为0.286%,平均每分钟就有6人被诊断为恶性肿瘤[1]。癌症是严重影响居民健康的危险因素,给患者家庭和社会带来沉重负担,近10年来全球范围内癌症负担呈持续增长趋势[2]。预计近几年我国癌症的发病率和死亡率仍将处于上升趋势,并随着危险因素的累积,癌症负担不容客观[3]。 展开更多
关键词 癌症 病耻感 测评工具 生活质量 护理
在线阅读 免费下载
饮食干预对癌症疼痛控制的影响
19
作者 康聪颖 范铭 《实用临床护理学电子杂志》 2019年第6期4-5,共2页
目的探讨饮食干预对癌症疼痛控制的影响。方法采用回顾性方法分析,选取我院自2016年1月-2018年1月的70例癌症患者的临床资料,随机将其分为两组,每组各35例,对照组采用常规饮食宣教,实验组在常规饮食宣教的基础上进行食谱设计饮食干预,... 目的探讨饮食干预对癌症疼痛控制的影响。方法采用回顾性方法分析,选取我院自2016年1月-2018年1月的70例癌症患者的临床资料,随机将其分为两组,每组各35例,对照组采用常规饮食宣教,实验组在常规饮食宣教的基础上进行食谱设计饮食干预,比较分析两组患者疼痛程度及营养状况。结果实验组无痛率为8.57%,明显高于对照组0.00%(P<0.05);实验组患者营养水平处于A级人数占42.86%明显高于对照组的17.14%(P<0.05)。结论癌症患者采用饮食干预可降低疼痛度,提高营养水平,促进患者早日康复,值得临床推广应用。 展开更多
关键词 癌症 饮食干预 疼痛 营养状况
在线阅读 免费下载
Compound Kushen injection combined with chemotherapy in the treatment of gastric cancer: a meta-analysis of randomized controlled trials 预览
20
作者 Su-Tong Liu Kai-Qi Su Wen-Xia Zhao 《TMR肿瘤》 2019年第1期118-126,共9页
Objective: This study aims to systematically evaluate the efficacy and safety of compound kushen injection (CKI) in combination with chemotherapy in patients with gastric cancer (GC). Methods: A comprehensive electron... Objective: This study aims to systematically evaluate the efficacy and safety of compound kushen injection (CKI) in combination with chemotherapy in patients with gastric cancer (GC). Methods: A comprehensive electronic search was conducted by searching PubMed, EMBASE, Cochrane Library, Chinese Biological Medical disc, China National Knowledge Infrastructure and Wanfang databases (the last update January 20, 2018). All randomized controlled trials (RCTs) of CKI plus chemotherapy versus chemotherapy alone in GC patients were identified. The quality of each study was evaluated using the Jadad’s scale, and the meta-analysis was performed using Review Manager 5.3 and STATA 14 software. Results: A total of nine studies on 688 cases were included in this study. The results showed that CKI combined with chemotherapy had a better effect on improving patients’ overall response rate (ORR) and life quality. The consequences of Egger’s and Begg’s tests showed there was no significant publication bias. Conclusion: The current evidence showed that CKI may enhance the clinical efficacy of chemotherapy, improve the quality of life and increase the safety in patients with gastric cancer. 展开更多
关键词 Compound kushen INJECTION CHEMOTHERAPY GASTRIC cancer RANDOMIZED controlled trials
在线阅读 下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部 意见反馈